Investment Rating - The report indicates a positive outlook for the industry, suggesting a focus on sectors with significant growth potential and strong domestic alternatives [4][29]. Core Insights - The market is currently experiencing a structural shift, with consumer sectors leading gains while growth sectors like computing hardware are under pressure. This reflects a broader risk-averse sentiment in the A-share market [4]. - Recent government policies aimed at promoting private investment in key sectors such as low-altitude economy and commercial aerospace are expected to benefit specialized and innovative companies in the North Exchange [4]. - The balance of market conditions is characterized by supportive policies and short-term emotional consolidation, creating opportunities for specialized companies, particularly in high-end manufacturing and renewable energy [4]. Summary by Sections Market Review - On November 10, the North Exchange A-share trading volume reached 20.18 billion yuan, a decrease of 1.314 billion yuan from the previous trading day. The North Exchange 50 Index closed at 1512.52, down 0.67%, with a PE_TTM of 71.78 times. The specialized and innovative index closed at 2506.89, down 0.99% [2][9]. - Among 282 companies listed, 127 saw gains, 10 remained flat, and 145 experienced declines. The top five gainers included Taipeng Intelligent (+13.6%) and Anda Technology (+13.0%), while the top five losers included Fangsheng Co. (-5.4%) and Haidar (-4.6%) [2][17][18]. Important News - The National Development and Reform Commission and the National Energy Administration issued guidelines to enhance renewable energy consumption and control, aiming for a multi-level consumption regulation system by 2030 [20]. - The State Council released measures to encourage private investment in projects such as railways and nuclear power, allowing private capital to hold over 10% in qualifying projects [21]. Company Announcements - Boshun Bio announced the purchase of wealth management products amounting to 20 million yuan using idle funds [22]. - Iron Tuo Machinery's major shareholder plans to reduce holdings by 1.05 million shares, accounting for 1.14% of total equity [23]. - Qianjin Technology reported using 45 million yuan of idle raised funds for cash management [24].

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The company is experiencing a steady recovery in growth momentum through channel optimization and product focus, with a 13.78% year-on-year decline in revenue for the first three quarters of 2025, totaling 3.464 billion yuan [1][4] - The third quarter revenue reached 1.092 billion yuan, showing a reduced decline of 9.95% compared to the previous quarter, indicating initial effectiveness of channel and product adjustments [1] - Key initiatives contributing to revenue improvement include the simplification of SKU and reduced promotions on low-margin products, alongside enhanced online channel operations [1] - The main brand, Winona, has shown stable performance, particularly during the Double Eleven pre-sale period, while the high-end anti-aging brand, Aikeman, has seen strong growth [1] Summary by Sections Revenue and Growth - The company achieved a total revenue of 3.464 billion yuan in the first three quarters of 2025, down 13.78% year-on-year, with a third-quarter revenue of 1.092 billion yuan, down 9.95% [1][3] - The revenue decline is narrowing, suggesting that operational adjustments are beginning to yield results [1] Profitability - The gross margin for Q3 2025 was 70.68%, a decrease of 5.67 percentage points year-on-year [2] - The net profit margin improved to 2.52%, indicating a significant enhancement in profitability compared to the same period last year [2] Future Outlook - The company is expected to continue its operational adjustments, with the performance during the Double Eleven sales event being a critical indicator of the effectiveness of its strategies [2] - The multi-brand matrix, anchored by Winona and supported by Aikeman and the newly introduced TriPollar brand, is anticipated to create a second growth curve [2] - EPS forecasts for 2025, 2026, and 2027 are projected at 1.02, 1.22, and 1.43 yuan respectively [2][3]

投资建议：当周北交所整体呈现缩量回调态势，表现弱于主要宽基指数。尽 管短期调整压力显现，但市场结构性特征显著：优质新股上市表现亮眼，政 策层面北交所加快推出北证 50ETF 等改革举措持续落地，叠加专精特新领 域长期政策支持，为机构投资者提供了布局细分赛道龙头的窗口。市场情绪 呈现"高波动、高分化"特点，资金向高流动性、高成长属性个股集中，估 值体系进一步向基本面靠拢。配置建议：（1）指数调整不改长期价值：北证 50 指数回调主要受市场风格切换影响，但其成分股盈利韧性优于中小盘整 体，估值性价比逐步显现；（2）政策红利持续释放：北证 50ETF 推出预期 明确，增量资金入市可期；专精特新"小巨人"企业持续获政策倾斜，技术 转化能力强的细分龙头具备长期成长空间；（3）市场结构优化提速：本周新 增上市企业覆盖体外诊断、工程咨询等新领域，北交所行业多元化程度提升， 为机构提供更丰富的配置标的。 风险提示：政策监管风险，北交所政策不及预期，行业竞争加剧风险。 分析师 曹森元 S0800524100001 19821289688 行业周报 | 北交所 上行中继盘整，关注成长空间大、确定性强的国产替代龙头 证券研究报告 ...

Group 1: Xinhua Insurance (601336.SH) - The core conclusion indicates that Xinhua Insurance's high equity investment ratio is expected to continue contributing to earnings elasticity as the capital market trends upward [6][7] - The liability side is undergoing a transformation towards dividend insurance, with accelerated growth in bancassurance channels and reforms in individual insurance channels, positioning the company for sustained business leadership [6] - The report anticipates significant profit improvement driven by dual efforts on both asset and liability sides, initiating coverage with a "Buy" rating [6] Group 2: Jinhua New Materials (920015.BJ) - Jinhua New Materials is positioned as a leading player in silane crosslinking agents, with stable growth expected in its core business and a second growth curve anticipated from hydroxylamine aqueous solution, which is set to break existing monopolies [9][10] - The company is projected to achieve total revenue of 1.04 billion, 1.31 billion, and 1.66 billion yuan from 2025 to 2027, with corresponding net profits of 200 million, 250 million, and 320 million yuan [9][10] - The current stock price corresponds to a PE ratio of 45.4, 35.8, and 28.0 for the years 2025 to 2027, with an initial coverage rating of "Add" [9][10] Group 3: Zhongke Feimeasure (688361.SH) - Zhongke Feimeasure is recognized as a leading provider of semiconductor quality control equipment, with a revenue of 702 million yuan in the first half of 2025, reflecting a year-on-year growth of approximately 51.39% [12][13] - The company is expected to achieve revenues of 2.061 billion, 3.128 billion, and 4.413 billion yuan from 2025 to 2027, with net profits projected at 184 million, 411 million, and 718 million yuan [12][13] - The current stock price corresponds to a PS ratio of 23.17, 15.27, and 10.82 for the years 2025 to 2027, with an initial coverage rating of "Add" [12][13] Group 4: Changan Automobile (000625.SZ) - Changan Automobile's sales in October 2025 reached 278,000 units, marking an 11% year-on-year increase, with cumulative sales from January to October totaling 2.374 million units, up 10% [15][17] - The company is expected to achieve revenues of 187 billion, 209.6 billion, and 229.7 billion yuan from 2025 to 2027, with year-on-year growth rates of 17.1%, 12.1%, and 9.6% [17] - The current stock price corresponds to an EPS of 0.64, 0.85, and 1.06 yuan for the years 2025 to 2027, maintaining a "Buy" rating [17] Group 5: Xingye Co., Ltd. (601799.SH) - Xingye Co., Ltd. reported a revenue of 10.71 billion yuan in the first three quarters of 2025, reflecting a year-on-year increase of 16.09%, with a net profit of 1.141 billion yuan, also up 16.76% [30][31] - The company is expected to achieve net profits of 1.719 billion, 2.115 billion, and 2.682 billion yuan from 2025 to 2027, maintaining a "Buy" rating [31][32] - The company is expanding into the robotics sector, indicating a strategic move towards new growth areas [31]

Investment Rating - The report gives a "Buy" rating for Xinhua Insurance (601336.SH) [5] Core Views - Xinhua Insurance's high equity investment ratio is expected to continue contributing to earnings elasticity as the capital market trends upward. The transformation of dividend insurance on the liability side, accelerated development of the bancassurance channel, and reforms in the individual insurance channel may help maintain the company's leading position. Coupled with significant dividend advantages, the company is expected to enhance profitability through dual efforts on both asset and liability sides [1][5] Summary by Sections Company Overview - Xinhua Insurance, established in September 1996, is one of the first batch of joint-stock insurance companies in China. It was listed on both the Hong Kong and Shanghai stock exchanges in December 2011, becoming the first A+H listed life insurance company in China. The company has shifted its focus towards dividend insurance in recent years [18][19] Liability Side: Four-Stage Evolution Towards High-Quality Transformation - The company has undergone four stages of evolution: 1. **2011-2016**: Implemented the "1-3-2" strategic layout focusing on customer-centricity and leveraging urbanization and aging opportunities. 2. **2016-2018**: Shifted towards value-oriented strategies, emphasizing regular premium and protection-type products. 3. **2019-2023**: Focused on channel expansion and scale-oriented growth. 4. **2024-Present**: Under new leadership, the company is enhancing professional market-oriented reforms and accelerating the transformation of dividend insurance [37][40][54] Asset Side: High Elasticity in the Equity Market - Since 2018, Xinhua Insurance has increased its allocation to equity assets, with a high equity investment ratio compared to peers. The company has actively responded to regulatory encouragement for long-term capital market participation, leading to a significant increase in equity investments. The company’s equity investment ratio ranks first among listed insurance companies [2][77] Profit Forecast and Valuation Outlook - The report forecasts Xinhua Insurance's operating revenue to reach 159.4 billion yuan in 2025, with a growth rate of 20.3%. The net profit attributable to shareholders is expected to be 37.1 billion yuan, reflecting a growth rate of 41.3% [12][3] Key Assumptions - The report anticipates a slowdown in premium growth in 2026 due to high base effects, with the bancassurance channel expected to maintain high growth rates. The new business value (NBV) is projected to grow significantly, supported by the transformation of dividend insurance and the ongoing recovery of the individual insurance channel [11][12]

Group 1 - The core conclusion of the report indicates a significant increase in the subscription enthusiasm for public REITs since the beginning of 2025, with subscription multiples reaching historical highs. However, there is a notable divergence between the primary and secondary markets, where new projects have high offline subscription multiples but experience significantly reduced first-day price increases, even hitting new lows for the year [1][10][12] - The report attributes this divergence to three main factors: a general decline in the secondary market, increased caution among investors, and a shift in market sentiment towards stricter quality requirements for underlying assets [1][12][16] - The report highlights that since July 2025, the first-day turnover rates of newly listed REITs have remained high, indicating a strong participation of short-term speculative funds that tend to sell off on the first day, exerting downward pressure on the secondary market [1][16][22] Group 2 - The report notes that the expansion of the inquiry range and the pricing of new projects close to the upper limit of the inquiry range have narrowed the valuation gap between the primary and secondary markets, thereby squeezing the profit margins in the secondary market [2][19] - It emphasizes that the recent phenomenon of divergence in the REITs market is a result of multiple factors, including asset quality, market sentiment, funding behavior, and pricing mechanisms. As the new subscription yields continue to converge, the market is expected to shift from "short-term speculation" to "long-term allocation" [1][22] - The report suggests that investors should be cautious when participating in primary subscriptions and focus more on the quality of underlying assets. It identifies water conservancy and heating projects as having higher operational stability among listed asset types, while new asset types may receive valuation premiums upon listing, particularly in port and cultural tourism assets [1][22] Group 3 - The credit bond market review indicates mixed performance in credit bond yields, with public bonds generally outperforming bank perpetual bonds. The yields of 5-year public bonds decreased by 4-6 basis points, while 7-year bonds saw a decline of 2-4 basis points [23][24] - The report states that the issuance scale and net financing scale of credit bonds increased week-on-week, with a total issuance of 4,671.65 billion yuan, up 1,253 billion yuan from the previous week [32] - It also highlights that the average issuance interest rate of credit bonds decreased to 2.15%, down 7.4 basis points week-on-week, with significant declines observed in financial bonds due to a higher proportion of AAA-rated bonds [39][40]

【宏观】10 月通胀数据点评：CPI 同比转正，PPI 环比回升 CPI 同比增速转正，环比明显高于去年同期。食品 CPI 环比增长，同比跌幅 收窄，猪肉价格对食品价格拖累仍然较大。核心 CPI 继续回升。PPI 环比转 正，同比跌幅收窄。过去几个月 PPI 有所企稳，对于企业盈利起到提振作用。 2026 年国内通胀有望回升。 【计算机】计算机行业 2025Q3 持仓分析：环比继续下滑仍处于低配区间 计算机行业 2025Q3 配置比例环比再次下降，重仓股配置比例为 2.6%（环 比-0.1pct），低配 2.2pct。 【计算机】德赛西威（002920.SZ）2025 年三季报点评：深化智能化战略， 低速无人车开启新篇章 我们预计公司 2025/2026/2027 年营业收入有望达到 327/398/494 亿元，我 们预计公司 2025/2026/2027 年归母净利润有望达到 25.3/32.6/40.8 亿元。 我们认为伴随公司新业务拓展，以及公司全球化布局加速，公司有望迎来新 增长周期。维持"买入"评级。 【医药生物】国邦医药（605507.SH）2025 三季报点评：盈利能力持续提 升，合作国资共谋 ...

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company reported a steady revenue growth of 6.56% year-on-year for the first three quarters of 2025, achieving a total revenue of 2.706 billion yuan, with a net profit attributable to shareholders of 309 million yuan, reflecting a 1.43% increase [1][2] - In Q3 2025, the company generated revenue of 960 million yuan, marking an 8.02% year-on-year growth, and a net profit of 126 million yuan, up by 1.00% [1][2] - The company is advancing its capacity expansion projects, with half of the new functional film material production capacity already operational and full production expected by H1 2026 [1] - The gross margin for the first three quarters of 2025 was 22.33%, a decrease of 0.63 percentage points year-on-year, while Q3 2025 saw a gross margin of 24.44%, an increase of 0.38 percentage points year-on-year [2] - The company anticipates revenue growth of 7.4%, 9.2%, and 9.8% for the years 2025, 2026, and 2027, respectively, with net profits expected to grow by 2.3%, 9.5%, and 13.6% in the same period [2] Summary by Sections Financial Performance - For Q1-Q3 2025, the company achieved a revenue of 2.706 billion yuan, with a net profit of 309 million yuan [1] - The gross margin for Q1-Q3 2025 was 22.33%, while Q3 2025 saw a gross margin of 24.44% [2] - The net profit margin for Q1-Q3 2025 was 11.43%, and for Q3 2025, it was 13.12% [2] Future Projections - Revenue projections for 2025, 2026, and 2027 are 3.788 billion yuan, 4.135 billion yuan, and 4.542 billion yuan, respectively [2] - Net profit projections for the same years are 478 million yuan, 524 million yuan, and 595 million yuan, respectively [2] - The expected EPS for 2025, 2026, and 2027 is 0.78 yuan, 0.86 yuan, and 0.97 yuan, respectively [2]

Investment Rating - The investment rating for the company is "Buy" [5][10] Core Insights - The company reported a revenue of 18.68 billion yuan for the first three quarters of 2025, a year-on-year increase of 6.67%, while the net profit attributable to the parent company was 2.435 billion yuan, a year-on-year decrease of 14.34% [1][5] - In Q3 2025, the company achieved a revenue of 6.019 billion yuan, a slight year-on-year decrease of 0.34%, and a net profit of 765 million yuan, down 20.73% year-on-year [1][5] - The overall gross margin improved to 22.19% in Q3, an increase of 0.34 percentage points quarter-on-quarter, although it decreased by 4.82 percentage points year-on-year [2][3] - The company has successfully optimized its customer structure, leading to a significant increase in average selling price (ASP) despite a decline in sales volume [1][2] Financial Summary - For the period of 2023 to 2027, the projected revenue is expected to grow from 20.114 billion yuan in 2023 to 32.247 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 12.8% [4] - The net profit attributable to the parent company is forecasted to increase from 3.2 billion yuan in 2023 to 4.722 billion yuan in 2027, with a notable growth rate of 17.6% in 2027 [4] - The earnings per share (EPS) is projected to rise from 2.74 yuan in 2023 to 4.05 yuan in 2027 [4] Operational Efficiency - The company has three out of four new production facilities achieving profitability as of Q3 2025, indicating improved operational efficiency [2][3] - The overall expense ratio for Q3 2025 was 5.46%, a decrease of 0.98 percentage points year-on-year, reflecting ongoing cost optimization efforts [2]

Global and A-share Market Overview - The A-share market showed mixed performance last week, with the Shanghai Composite Index increasing by 1.08% and the Hang Seng Index rising by 1.29%. The leading ETFs were primarily focused on the new energy sector [1][11][14]. - The top-performing A-share ETFs tracked indices related to electric grid equipment, photovoltaic leaders, and environmental protection, with significant gains of 11.42%, 10.66%, and 8.74% respectively [13][14]. ETF New Issuance Statistics - Last week, four stock ETFs were reported in the A-share market, with a total of 13 new stock ETFs established [1][16][20]. - The newly established ETFs included those tracking the ChiNext Composite Index and the IBOVESPA index from Brazil, with fund sizes of 3.26 billion and 3.00 billion respectively [20][21]. Fund Flow Analysis - In the A-share market, the top 10 ETFs by net inflow were predominantly from the financial sector, while the ETFs with the highest net outflows were broad-based indices like the CSI 300 and SSE 50 [2][23][24]. - The financial and biomedical sectors saw significant net inflows of 55.69 billion and 47.21 billion respectively, indicating strong investor interest [31][32]. ETF Strategy Performance - The performance of the diffusion indicator + RRG ETF rotation strategy yielded a return of 3.19%, outperforming the CSI Equal Weight Index and the CSI 300 Index by 2.18% and 2.37% respectively [4][29]. - The 50% base + intraday momentum strategy showed varying returns across different ETFs, with the Shanghai 50 ETF and CSI 300 ETF achieving returns of 0.47% and 0.52% respectively [4][29].